IL126591A - Saline dihydrate salts of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, -3-dihydro-2 (1H) - indole - 2one (= ziprasidone) And pharmaceutical preparations containing them - Google Patents

Saline dihydrate salts of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, -3-dihydro-2 (1H) - indole - 2one (= ziprasidone) And pharmaceutical preparations containing them

Info

Publication number
IL126591A
IL126591A IL12659197A IL12659197A IL126591A IL 126591 A IL126591 A IL 126591A IL 12659197 A IL12659197 A IL 12659197A IL 12659197 A IL12659197 A IL 12659197A IL 126591 A IL126591 A IL 126591A
Authority
IL
Israel
Prior art keywords
ziprasidone
dihydro
indol
chloro
compound
Prior art date
Application number
IL12659197A
Other languages
English (en)
Hebrew (he)
Other versions
IL126591A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL126591A0 publication Critical patent/IL126591A0/xx
Publication of IL126591A publication Critical patent/IL126591A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
IL12659197A 1996-05-07 1997-04-10 Saline dihydrate salts of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, -3-dihydro-2 (1H) - indole - 2one (= ziprasidone) And pharmaceutical preparations containing them IL126591A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07
PCT/IB1997/000393 WO1997042191A1 (en) 1996-05-07 1997-04-10 Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist

Publications (2)

Publication Number Publication Date
IL126591A0 IL126591A0 (en) 1999-08-17
IL126591A true IL126591A (en) 2001-11-25

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12659197A IL126591A (en) 1996-05-07 1997-04-10 Saline dihydrate salts of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, -3-dihydro-2 (1H) - indole - 2one (= ziprasidone) And pharmaceutical preparations containing them

Country Status (40)

Country Link
US (1) US6245765B1 (forum.php)
EP (1) EP0918772B1 (forum.php)
JP (1) JP3494659B2 (forum.php)
KR (1) KR100333215B1 (forum.php)
CN (1) CN1091769C (forum.php)
AP (1) AP765A (forum.php)
AR (1) AR007004A1 (forum.php)
AT (1) ATE278689T1 (forum.php)
AU (1) AU731267B2 (forum.php)
BG (1) BG63544B1 (forum.php)
BR (1) BR9709889A (forum.php)
CA (1) CA2252898C (forum.php)
CO (1) CO4940466A1 (forum.php)
CZ (1) CZ289215B6 (forum.php)
DE (1) DE69731094T2 (forum.php)
DK (1) DK0918772T3 (forum.php)
DZ (1) DZ2222A1 (forum.php)
EA (1) EA001190B1 (forum.php)
EG (1) EG24076A (forum.php)
ES (1) ES2229342T3 (forum.php)
GT (1) GT199700052A (forum.php)
HR (1) HRP970236B1 (forum.php)
ID (1) ID16867A (forum.php)
IL (1) IL126591A (forum.php)
IS (1) IS2080B (forum.php)
MA (1) MA24171A1 (forum.php)
MY (1) MY119997A (forum.php)
NO (1) NO312514B1 (forum.php)
NZ (1) NZ332218A (forum.php)
OA (1) OA10909A (forum.php)
PL (1) PL188330B1 (forum.php)
PT (1) PT918772E (forum.php)
SI (1) SI0918772T1 (forum.php)
SK (1) SK282837B6 (forum.php)
TN (1) TNSN97074A1 (forum.php)
TR (1) TR199802240T2 (forum.php)
TW (1) TW491847B (forum.php)
UA (1) UA46840C2 (forum.php)
WO (1) WO1997042191A1 (forum.php)
ZA (1) ZA973876B (forum.php)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
HUP0301747A2 (hu) * 2000-06-02 2003-09-29 Pfizer Products Inc. S-Metil-dihidro-zipraszidon pszichiátriai és szembetegségek kezelésére
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
KR20060011873A (ko) * 2003-05-16 2006-02-03 화이자 프로덕츠 인코포레이티드 비정형 항정신약과 ｇａｂａ 조절제, 항경련성 약물 또는 벤조다이아제핀의 치료 혼합물
US20050043324A1 (en) 2003-06-03 2005-02-24 Tamas Koltai Polymorphic forms of ziprasidone HCI and processes for their preparation
EP1628973A2 (en) 2003-10-24 2006-03-01 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
EP1753460A2 (en) * 2004-05-11 2007-02-21 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
EA200701065A1 (ru) * 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
CA2591670A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Process of preparing ziprasidone mesylate
EP1863806A1 (en) * 2005-02-11 2007-12-12 Teva Pharmaceutical Industries Ltd Amorphous ziprasidone mesylate
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
US20060270684A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Crystalline forms of ziprasidone mesylate
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
JP2010527925A (ja) * 2007-05-18 2010-08-19 サイドース・エルエルシー ジプラシドン製剤
JP2011526881A (ja) * 2008-06-25 2011-10-20 ファイザー・インク ジアリール化合物およびそれらの使用
JP5893616B2 (ja) * 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
CA2252895C (en) 1996-05-07 2002-08-20 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist

Also Published As

Publication number Publication date
BG63544B1 (bg) 2002-04-30
ES2229342T3 (es) 2005-04-16
ID16867A (id) 1997-11-20
SK150898A3 (en) 2000-02-14
AP765A (en) 1999-09-17
NO985194L (no) 1998-11-06
EP0918772B1 (en) 2004-10-06
OA10909A (en) 2001-10-26
IL126591A0 (en) 1999-08-17
SI0918772T1 (en) 2005-02-28
HRP970236B1 (en) 2002-12-31
AP9700976A0 (en) 1997-07-31
MY119997A (en) 2005-08-30
NO312514B1 (no) 2002-05-21
HRP970236A2 (en) 1998-06-30
GT199700052A (es) 2001-08-29
NZ332218A (en) 2005-02-25
HK1017892A1 (en) 1999-12-03
JP3494659B2 (ja) 2004-02-09
EA001190B1 (ru) 2000-12-25
PL188330B1 (pl) 2005-01-31
DE69731094D1 (de) 2004-11-11
WO1997042191A1 (en) 1997-11-13
IS2080B (is) 2006-02-15
AU731267B2 (en) 2001-03-29
TNSN97074A1 (fr) 2005-03-15
JPH11509867A (ja) 1999-08-31
CA2252898C (en) 2003-04-08
SK282837B6 (sk) 2002-12-03
KR20000010824A (ko) 2000-02-25
PL329884A1 (en) 1999-04-12
CA2252898A1 (en) 1997-11-13
DK0918772T3 (da) 2005-01-10
CZ349398A3 (cs) 1999-09-15
IS4874A (is) 1998-10-20
EG24076A (en) 2008-05-11
MA24171A1 (fr) 1997-12-31
PT918772E (pt) 2004-12-31
EP0918772A1 (en) 1999-06-02
UA46840C2 (uk) 2002-06-17
ATE278689T1 (de) 2004-10-15
DZ2222A1 (fr) 2002-12-03
DE69731094T2 (de) 2006-02-23
CN1216991A (zh) 1999-05-19
CZ289215B6 (cs) 2001-12-12
BG102892A (en) 1999-09-30
AR007004A1 (es) 1999-10-13
EA199800912A1 (ru) 1999-04-29
KR100333215B1 (ko) 2002-06-20
CN1091769C (zh) 2002-10-02
ZA973876B (en) 1998-11-06
AU2174797A (en) 1997-11-26
NO985194D0 (no) 1998-11-06
BR9709889A (pt) 1999-08-10
TR199802240T2 (forum.php) 1999-02-22
US6245765B1 (en) 2001-06-12
TW491847B (en) 2002-06-21
CO4940466A1 (es) 2000-07-24

Similar Documents

Publication Publication Date Title
AP838A (en) Mesylate trihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-y1)-1-piperaziny1)-ethy1) -6-chloro-1,3-dihydro-2h-indol-2-one.
AP765A (en) Ziprasidone mesylate dihydrates and its uses as dopamine D2 atagonists.
NZ508304A (en) Mesylate dihydrate salt of 5-(2-(4-(1,2 benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one ( ziprasidone) useful as dopamine D2 antagonist
MXPA98009242A (en) Salt mesylate trihydrate 5 - (- 2- (4- (1,2-benzoisotiazol-3-il) -1-piperazinil) ethyl) -6-chlorine-1,3-dihydro-2h-indol-2-

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees